Sanofi Ventures and Children's Hospital Colorado have returned to back Q32 Bio, an immune regulation-focused university spinout that has now raised at least $106m to date.

ORI Healthcare Fund II has a target of $400m and pharmaceutical firm Hepalink could potentially provide up to $80m for the vehicle.

4100 Group led an extension to the Stanford-StartX Fund-backed healthcare AI technology provider's latest round, which now stands at $30m.

4100 Group led an extension to the healthcare AI technology provider's latest round and was joined by several existing corporate investors.

The fitness and sleep tracker provider, an alumnus of Harvard Innovation Lab, was valued at $1.2bn in a round that took its total funding past $200m.

Spun out of University of Louisville, Koligo Therapeutics has already launched its first cell therapy product and aims to commercialise a treatment for covid-19.

The fitness and sleep tracker provider was valued at $1.2bn in a round that involved SoftBank Vision Fund coming on board as a new investor.

Eli Lilly has reinforced its partnership with the life sciences-focused venture firm, contributing to its TVM Life Science Innovation II vehicle.

Novartis has bought Vedere Bio, a retinal disease therapy spinout of UC Berkeley also exploiting UPenn research, to expand its gene medicine capabilities.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.